DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer
NCT05504707
Recruiting
The purpose of the study is to find out if an investigational vaccine called Dendritic Cell (DC) vaccine given together with standard of care chemotherapy drugs can help people with Triple Negative and HR low positive breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/18/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Triple Negative Breast Cancer, HER2-negative Breast Cancer
Register for Updates
CBT Augmentation to Promote Medication Discontinuation in Pediatric OCD
NCT05609916
Recruiting
The purpose of this study is to examine whether youth with OCD who benefit from CBT augmentation to SRI can discontinue their medication without relapse over 24 weeks.
Gender:
ALL
Ages:
Between 7 years and 17 years
Trial Updated:
07/18/2025
Locations: Baylor College of Medicine, Houston, Texas
Conditions: Cognitive Behavioral Therapy, Obsessive-Compulsive Disorder, Obsessive-Compulsive Disorder in Children, Obsessive-Compulsive Disorder in Adolescence
Register for Updates
Daratumumab in Primary Antiphospholipid Syndrome
NCT05671757
Recruiting
The purpose of this study is to see if the study medication, daratumumab, is safe to treat individuals with Anti-Phospholipid Syndrome (APS). Three daratumumab dosing cohorts are planned with up to six participants in each dosing cohort with the potential to enroll an additional 4 subjects in the highest safe dose (HSD) cohort, for a total of up to 22 participants. The dosing cohorts are: 4 mg/kg, 8 mg/kg, and 16 mg/kg. Each cohort will receive intravenous (IV) administration of daratumumab acc... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/18/2025
Locations: Johns Hopkins University, Baltimore, Maryland +7 locations
Conditions: Autoimmune Disorders
Register for Updates
Optimizing Ultrasound-induced Anti-inflammation in Human Subjects
NCT05685108
Recruiting
This is a feasibility study to determine whether pulsed ultrasound stimulation targeting the splenic nerve or the cervical vagus nerve can elicit an anti-inflammatory immune response in healthy volunteers.
Gender:
ALL
Ages:
Between 25 years and 50 years
Trial Updated:
07/18/2025
Locations: University of Virginia, Division of Nephrology; Center for Immunity, Inflammation & Regenerative Medicine, Charlottesville, Virginia
Conditions: Healthy Subjects
Register for Updates
A Study of Oral Minoxidil to Treat Hair Loss in Children, Teens, and Young Adults Who Are Cancer Survivors
NCT05778825
Recruiting
This study will test whether minoxidil taken by mouth (oral minoxidil) can improve hair loss caused by cancer treatment in children and young adults. In addition, the researchers will test the safety of oral minoxidil, and see if the study drug causes few or mild side effects in participants. Other purposes of this study include looking at whether participants are able to follow their study drug dosing schedules, and how oral minoxidil affects participants' quality of life.
Gender:
ALL
Ages:
Between 6 years and 18 years
Trial Updated:
07/18/2025
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Survivors of Childhood Cancer, Alopecia
Register for Updates
A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)
NCT05785767
Recruiting
This study is researching an experimental drug called fianlimab (also called REGN3767), combined with a medication called cemiplimab (also called REGN2810), individually called a "study drug" or collectively called "study drugs". The study is focused on patients who have advanced non-small cell lung cancer (NSCLC). The aim of the study is to see how effective the combination of fianlimab and cemiplimab is in treating advanced NSCLC, in comparison with cemiplimab by itself. The study is looking... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/18/2025
Locations: Arizona Clinical Research Center, Tucson, Arizona +112 locations
Conditions: Advanced Non-Small Cell Lung Cancer
Register for Updates
A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer
NCT05800015
Recruiting
This study is researching an investigational drug called fianlimab (also called REGN3767) with two other medications called cemiplimab and chemotherapy, individually called a "study drug" or collectively called "study drugs". 'Investigational' means that the study drug is not approved for use outside of this study by any Health Authority. Examples of chemotherapy drugs include the following: Paclitaxel plus carboplatin, and Pemetrexed plus cisplatin. The study is being conducted in patients who... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/18/2025
Locations: Arizona Clinical Research Center, Tucson, Arizona +76 locations
Conditions: Non-small Cell Lung Cancer
Register for Updates
A Novel Therapy for Breast Cancer Survivors With Genitourinary Syndrome of Menopause
NCT05812924
Recruiting
The purpose of this study is to determine whether platelet rich plasma (PRP) injections to the vulva and vagina will improve symptoms of genitourinary syndrome of menopause (GSM) in breast cancer patients.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/18/2025
Locations: University of Miami, Miami, Florida
Conditions: Breast Cancer, Genitourinary Syndrome of Menopause
Register for Updates
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
NCT05835310
Recruiting
A Study to evaluate the PK, PD, efficacy, and safety of Anifrolumab in children with moderate to severe active SLE
Gender:
ALL
Ages:
Between 5 years and 17 years
Trial Updated:
07/18/2025
Locations: Research Site, Phoenix, Arizona +91 locations
Conditions: Systemic Lupus Erythematosus
Register for Updates
Detoxification of the Liver In PSC (Dolphin)
NCT05835505
Recruiting
This study is a clinical trial being done to investigate the efficacy of drug BRS201 (hydroxocobalamin) as a treatment in patients with primary sclerosing cholangitis. Participation in this study will take 8 weeks long and the study is structured as a cross-over study in which participants will take the study drug for 4 weeks and a placebo drug for 4 weeks in a randomized order in the form of an oral medication. Participation may also involve receiving an IV dose of the medication. The study wil... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/18/2025
Locations: Brigham and Women's Hospital, Chestnut Hill, Massachusetts
Conditions: Primary Sclerosing Cholangitis
Register for Updates
Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer
NCT05873192
Recruiting
To learn about the effectiveness of adding talazoparib to the standard of care treatment combination of androgen ablation therapy (hormone therapy, also known as ADT) and enzalutamide in patients with prostate cancer that has spread into the lymph nodes.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
07/18/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Prostate Cancer
Register for Updates
Examining the Effects of Intra-detrusor Botox at Time of HoLEP in Men With Overactive Bladder Symptoms
NCT05878951
Recruiting
The objective of our multi-center randomized single-blind study is to examine the safety and effect of intra-detrusor OnabotulinumtoxinA injections at the time of holium laser enucleation of the prostate (HoLEP) in men with overactive bladder symptoms with and without urge incontinence.
Gender:
MALE
Ages:
Between 18 years and 89 years
Trial Updated:
07/18/2025
Locations: Northwestern Medicine, Chicago, Illinois
Conditions: Urinary Incontinence, Overactive Bladder Syndrome, Overactive Bladder, Urologic Diseases
Register for Updates